Retatrutide has emerged as a new medication in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in research studies. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesinsulin secretion, and ultimately results in significant reduction in bod